Answers are grounded in this paper and cite their sources.
For the purpose of making a total synthesis of bacitracin A, a protected heptapeptide with a ring structure, Nα- (formyl-l-isoleucyl)-cyclo-(l-lysyl-δ-tosyl-d-ornithyl-l-isoleucyl-d-phenyl-alanyl-im-benzyl-l-histidyl-α-methyl-β-l-aspartyl) was first prepared by a high dilution method. After deformylation, it was coupled with a tetrapeptide corresponding to the N-terminal part of bacitracin A, the benzyloxycarbonyl-l-isoleucyl-S-benzyl-l-cysteinyl-l-leucyl-d-glutamic acid (α-azide)-γ-t-butyl ester, to afford an undecapeptide derivative. This was converted to a hydrazide, which was then coupled with β-benzyl-d-isoasparaginate to give the Nα-(benzyloxycarbonyl-l-isoleucyl-S-benzyl-l-cysteinyl-l-leucyl-γ-t-butyl-d-glutamyl-d-isoleucyl)-cyclo-(l-lysyl-δ-tosyl-d-ornithyl-l-isoleucyl-d-phenylalanyl-im-benzyl-l-histidyl-β-l-aspartyl)-d-isoasparagine β-benzyl ester. The removal of all protecting groups from it gave a free dodecapeptide, which has the same amino acid sequence, including optical properties, as that of the structure of bacitracin A proposed by Stoffel and Craig; it is different from the latter only in having the thiazoline ring replaced with the cysteine residue. The synthetic dodecapeptide was tested for biological activity and for the formation reaction of the thiazoline ring.
No takes yet. Share an insight, caveat, or question.
Ariyoshi et al. (1967) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: